Animal Model Market Size, Share and Growth Outlook, 2026

Animal Model Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Animal Model Market size is forecast to increase from $2.96 Billion in 2026 to $5.52 Billion in 2034 at a CAGR of 8.1% between 2026 and 2034.

The Animal Model market report provides detailed analysis and outlook of Animal Model segments including By Animal Type (Mice, Rats, Fish, Birds, Guinea Pigs & Rabbits, Cattle & Large Animals, Non-Human Primates), By Technology (Genetically Engineered Models, Conventional/Inbred Models, Hybrid/Outbred Models, Humanized Models), By Application (Oncology Research, Neurology & Psychiatry, Cardiovascular & Metabolic Disorders, Immunology & Infectious Diseases, Toxicology & Safety Assessment, Basic & Academic Research), By Service (Breeding & Colony Management, Cryopreservation & Quarantine, Genetic Testing & Validation, Model Outsourcing/CRO Services), By End User (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations, Academic & Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Animal Model Industry Overview

Strategic Collaborations Accelerating Translational Research and Drug Discovery

The animal model industry remains a critical component of biomedical research, supporting drug discovery, antibody development, disease modeling, and preclinical evaluation across pharmaceutical and biotechnology sectors. A notable industry development is the collaboration between The Jackson Laboratory and AbTherx, which aims to accelerate next-generation antibody discovery and therapeutic development. The partnership combines The Jackson Laboratory’s extensive expertise in preclinical animal models and translational research infrastructure with AbTherx’s advanced antibody engineering platform. This integrated approach is designed to enhance candidate selection, improve preclinical validation, and shorten development timelines for innovative biologic therapies. Such collaborations highlight the continuing importance of animal models in bridging the gap between laboratory research and clinical application.

Regulatory Changes Driving Adoption of Alternative Research Technologies

The industry is undergoing significant transformation following the implementation of regulatory reforms that expand the acceptance of non-animal testing methodologies. The U.S. FDA Modernization Act has removed the requirement that all drug approvals must rely on in vivo animal studies, creating opportunities for broader adoption of New Approach Methodologies (NAMs). These include organoids, organ-on-chip platforms, and artificial intelligence-driven computational models that can simulate biological responses with increasing accuracy. Pharmaceutical and biotechnology companies are incorporating these technologies into early-stage drug development workflows to improve screening efficiency and reduce development costs. As a result, alternative testing platforms are becoming valuable tools for candidate prioritization before progression into traditional animal studies.

Patient-Derived Organoids Reshaping Oncology Research

Cancer research is experiencing a notable shift toward more clinically relevant experimental models. Scientific and policy discussions increasingly emphasize the growing role of patient-derived organoids in oncology research and precision medicine applications. These three-dimensional cellular models replicate individual patient tumor characteristics, enabling researchers to evaluate drug responses in a highly personalized manner. Organoid-guided testing is being incorporated into clinical research programs to improve translational relevance and enhance prediction of therapeutic outcomes. While animal models continue to play an essential role in studying whole-body physiological responses, immune interactions, and systemic drug effects, the increasing adoption of organoid technologies is reducing dependence on animal testing during early-stage oncology research. This evolving research ecosystem is fostering a more integrated approach that combines advanced in vitro systems, computational modeling, and animal studies to support more efficient and predictive therapeutic development.

Animal Model Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Animal Model market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Charles River Laboratories International, Inc., The Jackson Laboratory, Taconic Biosciences, Inc., Envigo (Inotiv, Inc.), Janvier Labs, GenOway S.A., Eurofins Scientific SE, Pharmaron Beijing Co., Ltd., Crown Bioscience, Inc., Biocytogen Pharmaceuticals. The Animal Model market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Animal Model industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Animal Model Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Animal Model companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Animal Model markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Animal Model Market Competitive Benchmarking and Company Analysis

Leading companies in Animal Model industry include- Charles River Laboratories International, Inc., The Jackson Laboratory, Taconic Biosciences, Inc., Envigo (Inotiv, Inc.), Janvier Labs, GenOway S.A., Eurofins Scientific SE, Pharmaron Beijing Co., Ltd., Crown Bioscience, Inc., Biocytogen Pharmaceuticals. The Animal Model market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Animal Model Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Animal Model market remains one of the strongest-performing segments in the country.
The US Animal Model Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Animal Model market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Animal Model industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Animal Model markets

Canada's strong Animal Model sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Animal Model market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Animal Model Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Animal Model market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Animal Model population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Animal Model industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Animal Model market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Animal Model sales through 2034

France Animal Model companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Animal Model Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Animal Model distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Animal Model Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Animal Model market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Animal Model industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Animal Model industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Animal Model Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Animal Model market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Animal Model market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Animal Model Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Animal Model Market Segmentation

By Animal Type
Mice
Rats
Fish
Birds
Guinea Pigs & Rabbits
Cattle & Large Animals
Non-Human Primates
By Technology
Genetically Engineered Models
Conventional/Inbred Models
Hybrid/Outbred Models
Humanized Models
By Application
Oncology Research
Neurology & Psychiatry
Cardiovascular & Metabolic Disorders
Immunology & Infectious Diseases
Toxicology & Safety Assessment
Basic & Academic Research
By Service
Breeding & Colony Management
Cryopreservation & Quarantine
Genetic Testing & Validation
Model Outsourcing/CRO Services
By End User
Pharmaceutical & Biopharmaceutical Companies
Contract Research Organizations
Academic & Research Institutes

Top Companies in Animal Model Industry

Charles River Laboratories International, Inc.
The Jackson Laboratory
Taconic Biosciences, Inc.
Envigo (Inotiv, Inc.)
Janvier Labs
GenOway S.A.
Eurofins Scientific SE
Pharmaron Beijing Co., Ltd.
Crown Bioscience, Inc.
Biocytogen Pharmaceuticals

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025